Yenal Dundar

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 12

Top Venues

PharmacoEconomics - open

BMC cancer

International journal of technology assessment in health care

Central Queensland Hospital and Health Service

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Central Queensland Hospital and Health Service Mar 02 2020

Australia

Consultant Psychiatrist :: Mental Health

University of Liverpool Oct 22 2001

United Kingdom

Research Fellow :: Health Sciences

Publications

Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Rebecca Bresnahan, Rachel Houten, Janette Greenhalgh, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Devarshi Bhattacharyya, Yenal Dundar, Joanne McEntee, Shreyans Gandhi, Nigel Fleeman, Marty Chaplin
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Nigel Fleeman, Rachel Houten, Marty Chaplin, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Rui V Duarte, Aditya Shenoy
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC cancer 19 (1) (2019)
Nigel Fleeman, Yenal Dundar, Prakesh S Shah, Ben Nj Shaw
Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. International journal of technology assessment in health care 35 (4) (2019)

Yenal Dundar.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yenal Dundar